14th March 2019. OCB is proud to announce that an article on challenges and solutions in patient treatment strategies for stage II colon cancer has been published in Gastroenterology Report. The publication reviews the options for measuring biomarkers associated with stratifying the risks associated with Stage II colorectal cancers using diagnostics, utilizing both currently available and novel technologies. The review describes the challenges in treatment decisions for early-stage colon cancer and how personalised medicine can assist clinicians in making the best treatment choices for patients with stage II colon cancer in particular.
Dr Susan Fotheringham, Dr Guy Mozolowski and intern medical student Ellie Murray were supported by Professor David Kerr in writing this article. It underlines OCB’s commitment to supporting clinicians with science and quality of information.
Please follow the link to read the abstract https://academic.oup.com/gastro/advance-article-abstract/doi/10.1093/gastro/goz006/5375423
Contact
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743